About this trial
We hypothesize vascular beta3 adrenergic receptors are present and functional in aging women and can be targeted to attenuate sympathetic vasoconstriction and enhance vascular function in aging women.
Eligibility criteria
Qualifiers
None
Disqualifiers
None
Trial design
Treatments tested in this trial
- Placebo
- Gemtesa
Treatment groups
60 Participants
are divided into 2 treatment groupsLocations
1University of Missouri65211, ColumbiaMissouri, United States
Sponsors and collaborators
University of Missouri-Columbia
Lead sponsor
Source ClinicalTrials.gov